Production (Stage)
Sharp Therapeutics Corp.
SHRXF
$1.29
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 419.63% | 0.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 238.24% | 0.00% | |||
| Operating Income | -238.24% | 0.00% | |||
| Income Before Tax | -2,787.84% | 0.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2,787.84% | 0.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2,787.84% | 0.00% | |||
| EBIT | -238.24% | 0.00% | |||
| EBITDA | -239.97% | 0.00% | |||
| EPS Basic | -1,730.16% | 0.00% | |||
| Normalized Basic EPS | -549.55% | 0.00% | |||
| EPS Diluted | -1,730.16% | 0.00% | |||
| Normalized Diluted EPS | -549.55% | 0.00% | |||
| Average Basic Shares Outstanding | 58.04% | 0.00% | |||
| Average Diluted Shares Outstanding | 58.04% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||